| ²é¿´: 696 | »Ø¸´: 3 | ||
guojingtaoÌú³æ (СÓÐÃûÆø)
|
[ÇóÖú]
¶®ÁÙ´²Ò½Ñ§µÄ°ï¿´¿´Õâ¶ÎÎÄ×ÖÊÇɶÒâ˼£¿
|
|
Stroke or systemic embolism occurred in 182 patients receiving 110 mg of dabigatran (1.53% per year), 134 patients receiving 150 mg of dabigatran (1.11% per year), and 199 patients receivingwarfarin (1.69% per year) (Table 2 and Fig. 1). Both doses of dabigatran were noninferior to warfarin (P<0.001). The 150-mg dose of dabigatran was also superior to warfarin (relative risk, 0.66; 95% confidence interval [CI], 0.53 to 0.82; P<0.001), but the 110-mg dose was not (relative risk, 0.91; 95%CI, 0.74 to 1.11; P = 0.34). Rates of hemorrhagic stroke were 0.38% per year in the warfarin group, as compared with 0.12% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.31; 95% CI, 0.17 to 0.56; P<0.001) and 0.10% per year in the group that received 150 mg of dabigatran (relative risk, 0.26; 95% CI, 0.14 to 0.49; P<0.001). ÉÏÃæÕâ¶Î»°ÓÐËÄܰïÎÒ½²½²£¬The 150-mg dose of dabigatran was also superior to warfarin (relative risk, 0.66; 95% confidence interval [CI], 0.53 to 0.82; P<0.001)Õâ¾ä»°ÖÐ0.66,95%£¬0.53-0.82¡¢p¶¼ÊÇʲôº¬Ò壿ͨ¹ýÕâ¸ö¿É¿´³ö´ï±È¼ÓȺõ¥È«ÉíÐÔ˨Èû·¢ÉúÂʵÍÓÚ»ª·¨ÁÖô£¿relative riskÊÇʲôÒâ˼£¿In this noninferiority trial, ÎÄÕÂÖÐÌáµ½ÁË·ÇÁÓЧÐÔÊÔÑ飬ÊDz»ÊÇÖ»×ö·ÇÁÓЧÐÔÊÔÑé¾Í¿ÉÒÔÖ¤Ã÷Ò©ÎïµÄÓÐЧÐÔ£¿ |
» ²ÂÄãϲ»¶
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ4È˻ظ´
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´
ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
ÕæÇ¿±ØÊ¤: ½ð±Ò+1, лл 2014-11-05 08:43:33
ÕæÇ¿±ØÊ¤: ½ð±Ò+1, лл 2014-11-05 08:43:33
|
ÄѵÀûѧ¹ýͳ¼ÆÑ§£¿»¹ÊǶ¼»¹¸øÀÏʦÁË£¿ relative riskÊÇÏà¶Ô·çÏÕ£¬ÊÇÖ¸Ò»¸öȺÌ屩¶ÔÚÒ»¶¨·çÏÕÏÂÓëδ±©Â¶Ôڸ÷çÏÕÏÂijʼþ·¢Éú¸ÅÂʵıÈÖµ¡£ 95%CI£¬Îª95%¿ÉÐÅÇø¼ä¡£»¹¼ÇµÃÕý̬·Ö²¼Â𣿾ÍÊÇ5%ºÍ95%Ö®¼äµÄÇøÓò¡£ P<0.001ÄѵÀ»¹ÐèÒª½âÊÍ£¿ÕâÊÇͳ¼Æ½á¹¹£¬Ò»°ãp<0.05±íʾÓÐÏÔÖøÍ³¼ÆÑ§ÒâÒå... Äã5½ð±ÒÎÒ¸ÉÂð¸øÄã½âÊÍÕâôÏêϸ£¿ ![]() àÞ£¬»¹ÓÐ noninferiority trial ·ÇÁÓЧÐÔÁÙ´²ÊÔÑéÊÇÆÀ¼ÛÊÔÑéÒ©µÄÖÎÁÆÐ§¹û²»±ÈÑôÐÔ¶ÔÕÕÒ©²îµÄÁÙ´²ÊÔÑ飬ĿµÄÔÚÓÚÖ¤Ã÷ÊÔÑéÒ©ÎïÓëËùÑ¡¶¨µÄÑôÐÔ¶ÔÕÕÒ©µÄÁÆÐ§²î±ðºÜС£¬ÕâôСµÄ²îÒìûÓÐÁÙ´²ÉÏÒâÒå¡£ |
2Â¥2014-10-11 10:50:08
guojingtao
Ìú³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 224.9
- É¢½ð: 5
- Ìû×Ó: 68
- ÔÚÏß: 114.2Сʱ
- ³æºÅ: 606092
- ×¢²á: 2008-09-18
- ÐÔ±ð: GG
- רҵ: É«Æ×·ÖÎö
3Â¥2014-10-11 11:31:34
ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
4Â¥2014-10-11 11:35:21














»Ø¸´´ËÂ¥